Several studies have used liver cancer cell lines, including HepG2, Hep3B, and SNU-449, to characterize TGF-β1-induced EMT in HCC, showing different degrees of treatment response and variability in the activated molecular programs [19,32,33]. Here, TGFB1 is linked to hepatocellular carcinoma.